JAGX stock rating and analysis - Jaguar Health Inc : a summary of key financial strength and profitability metrics. Company Plans to File Q1 2020 10-Q on May 14, 2020 SAN FRANCISCO, CA / ACCESSWIRE / May 12, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company management will host a conference call on Friday, May 15, 2020 at 8:30 a.m. Canalevia is the first and only oral plant-based prescription drug candidate for EID in dogs Diarrhea is a common problem among working dogs subjected to intense, long-duration off-leash exercise SAN FRANCISCO, CA / ACCESSWIRE / May 12, 2020 / Jaguar Health, Inc. Jaguar concurrently receives $1.5 million and exclusive 10-year license from purchaser to develop and commercialize NP-500 through sale of NP-500 technology and IP Deal brings in immediate non-dilutive capital to fund pipeline of plant-based prescription drug candidates of Jaguar's Napo, Mytesi ® net sales and gross sales grew 38% and 44%, respectively, in 2019 compared to 2018 Reminder: Company to host investor call Monday, April 6 at 8:30 a.m. Eastern SAN FRANCISCO, CA / ACCESSWIRE / April 6, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported. Nos partenaires et nous-mêmes stockerons et/ou utiliserons des informations concernant votre appareil, par l’intermédiaire de cookies et de technologies similaires, afin d’afficher des annonces et des contenus personnalisés, de mesurer les audiences et les contenus, d’obtenir des informations sur les audiences et à des fins de développement de produit. Share your opinion and gain insight from other stock traders and investors. Related Link: ET SAN FRANCISCO --(BUSINESS WIRE)--Jan. Management will also be available to schedule meetings outside of the conference SAN FRANCISCO --(BUSINESS WIRE)--Jan. 5, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for, SAN FRANCISCO --(BUSINESS WIRE)--Dec. 19, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, today announced that, SAN FRANCISCO --(BUSINESS WIRE)--Dec. 12, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, today announced that, Jaguar Also Hosted a Dinner Discussion Gathering During AAEP with Equine Veterinarian Opinion Leaders in Support of the Company’s Clinical Development Efforts SAN FRANCISCO --(BUSINESS WIRE)--Dec. 9, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on, SAN FRANCISCO --(BUSINESS WIRE)--Nov. 23, 2016-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, announced today that, A Full Analysis of the Study Data with Scoring of Squamous and Glandular Ulcers is Expected to be Available in January SAN FRANCISCO --(BUSINESS WIRE)--Nov. 14, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing, Statistically Significant Final Results Confirm Interim Conclusion That Crofelemer Treatment is Superior to Placebo SAN FRANCISCO --(BUSINESS WIRE)--Oct. 18, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class, Merger Would Allow Jaguar to Recognize an Important Revenue Stream from First-in-Class, Novel Mechanism of Action of the Anti-diarrheal Mytesi SAN FRANCISCO --(BUSINESS WIRE)--Oct. 6, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and. A high-level overview of Jaguar Health, Inc. (JAGX) stock. Statistically Significant Results Support the Conclusion that Canalevia Treatment is Superior to Placebo 91.0% of Treated Dogs Achieved a Formed Stool During the Study Versus 50.0% of Placebo-treated Animals San Francisco, CA (February 19, 2015): Jaguar Animal Health, Inc. Drug Candidate Addresses Gastric, Intestinal and Colonic Ulcers in Horses and Foals San Francisco, CA (February 10, 2015): Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal and other proprietary health products, Jaguar Exhibiting at World Ag Expo & Western Veterinary Conference this Month San Francisco, CA (February 5, 2015): Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production, Canalevia™ is a New Prescription Drug Candidate for Treatment of Dogs Undergoing Chemotherapy San Francisco, CA (December 22, 2014): Jaguar Animal Health, Inc., an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production, San Francisco, CA (December 4, 2014): Jaguar Animal Health, Inc. (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has completed a study designed to, San Francisco, CA (November 21, 2014): Jaguar Animal Health, Inc. (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has appointed Tim Dotson, a, ANIMART Named First Commercial Partner September 29, 2014 08:30 AM Eastern Daylight Time SAN FRANCISCO--( BUSINESS WIRE )--Today, Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and, SAN FRANCISCO--( BUSINESS WIRE )--Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal and other proprietary health products for companion and production animals, announced today that it has submitted its eighth, 09:38 AM Eastern Daylight Time SAN FRANCISCO--( BUSINESS WIRE )--Jaguar Animal Health, Inc., (“Jaguar” or the “Company”) an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, today named Ian Parker, a, March 03, 2014 03:15 PM Eastern Standard Time SAN FRANCISCO--( BUSINESS WIRE )--Jaguar Animal Health, Inc. (“Jaguar”) announced today that it has submitted three Investigational New Animal Drug Applications (“INADA”) with the Center for Veterinary Medicine of the US Food and Drug Administration, SAN FRANCISCO , Feb. 5, 2014 /PRNewswire/ -- Jaguar Animal Health, Inc. ("Jaguar") announced an initial $2 million closing of its Series A round of financing. Jaguar Health - Jaguar Health. Jaguar Animal Health, Inc. Team of advisors will guide strategic research to discover and develop potential novel, natural psychoactive prescription medicines derived from Jaguar's library of 2,300 plants SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2020 /   Jaguar Health, Inc. SAN FRANCISCO, CA / ACCESSWIRE / September 11, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) announced today announced that Lisa Conte , Jaguar's founder, president and CEO, will present at the virtual 2020 H.C. Wainwright 22 nd Annual Global Investment Conference on Wednesday, September 16, 2020 , at, The Fourth Tranche Accounts Receivable has a gross value of $2,329,662.72 , representing customer billings over a 24-day period SAN FRANCISCO, CA / ACCESSWIRE / September 10, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar and its wholly owned subsidiary, Napo, Initiative includes leading ethnobotanists and will leverage Jaguar's plant-based medicines expertise and proprietary library of 2,300 medicinal plants Jaguar and its subsidiary Napo Pharmaceuticals uniquely suited to lead this effort based on successful development and commercialization of Napo's, Amount Exceeds Minimum Stockholders' Equity Requirement for Initial Listing on The Nasdaq Capital Market SAN FRANCISCO, CA / ACCESSWIRE / September 2, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company has completed transactions that it believes, Company shares updates on investigator-initiated trials of crofelemer (Mytesi ® ), a novel FDA-approved plant-based oral prescription medicine SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) today provided updates regarding ongoing investigator-initiated. San Francisco, CA : Jaguar Animal Health, Inc. (Nasdaq: JAGX), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today the pricing of its initial public offering of 2,860,000 shares of its common stock … Provides Second Quarter 2018 Financial Updates, Jaguar Health (NASDAQ: JAGX) Subsidiary Napo Pharmaceuticals and RedHill Biopharma Enter U.S. Co-Promotion Agreement for Mytesi, Napo's FDA-Approved Drug Product, Jaguar Health Appoints Pharmaceutical Industry Veteran David MacNaughtan to Board of Directors, Jaguar Health Appoints Senior Commercial Pharmaceutical Executive Greg Divis to Board of Directors, Napo Pharmaceuticals Presents New Data at the 13th International Conference on HIV Treatment and Prevention Adherence Regarding the Use of Mytesi (Crofelemer) to Treat Noninfectious Diarrhea in HIV Patients, Jaguar Health, Inc. 28, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, announced today that, SAN FRANCISCO --(BUSINESS WIRE)--Mar. Important Safety Information about MYTESI ® MYTESI ® is not indicated for the treatment of infectious diarrhea. Shares of Common Stock to Begin Trading on Split-Adjusted Basis on June 7, 2019 SAN FRANCISCO, CA / ACCESSWIRE / June 6, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal Toggle Summary 06/05/19: Jaguar Health CEO and Board Members Invest in Bridge … Napo to host virtual workshop September 30 th about the GI consequences of HIV SAN FRANCISCO, CA / ACCESSWIRE / September 28, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) announced today that the company's wholly owned subsidiary, Napo Pharmaceuticals, Inc. Merger Will Provide an Important Revenue Stream to Jaguar from Mytesi, an FDA Approved Napo Anti-Diarrheal Launched October 2016 Offering a First-in-Class, Novel Mechanism of Action Highly Conserved Across All Mammals SAN FRANCISCO --(BUSINESS WIRE)--Mar. "We remain fully committed to expanding access to Mytesi, April 2020 sales of Mytesi ® generate gross accounts receivable of $2,753,639 SAN FRANCISCO, CA / ACCESSWIRE / May 13, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar and its wholly owned subsidiary, Napo Pharmaceuticals, Inc. , (collectively, the "Company") have jointly. Rule out infectious etiologies of diarrhea before starting MYTESI ®. Shares of Jaguar Health (NASDAQ: JAGX) soared 49.3% on Friday, extending the pharmaceutical company's staggering gains since mid-November. SAN FRANCISCO --(BUSINESS WIRE)--Jul. Webcast registration link appears below Jaguar CEO Lisa Conte interviewed on Innovators with Jane King SAN FRANCISCO, CA / ACCESSWIRE / January 12, 2021 /   Jaguar Health, Inc. New COVID-19 strain estimated to have tripled number of infections in England during November 2020 lockdown Investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time . Company Plans to File Q2 2020 10-Q on August 13, 2020 Save the Date: Company to host virtual disease awareness event on October 20, 2020 focused on cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / August 11, 2020 /   Jaguar Health, Inc. A significant proportion of patients undergoing cancer therapy experience diarrhea SAN FRANCISCO, CA / ACCESSWIRE / August 6, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today the activation of the investigational new drug (IND) application filed by the, SAN FRANCISCO, CA / ACCESSWIRE / July 22, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that effective June 16, 2020 , the Company has granted nonstatutory stock options for the purchase of up to 30,000 shares of the Company's common stock to one new, SAN FRANCISCO, CA / ACCESSWIRE / July 22, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the 28-day preclinical toxicology and safety study in rats began yesterday to support development of lechlemer, the second generation, plant-based anti-secretory. ET on InvestorPlace.com. 14, 2017-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, announced today that it, Management will be available to schedule meetings during the conference SAN FRANCISCO --(BUSINESS WIRE)--Mar. ACST Stock: 13 Things to Know … *Indication MYTESI ® is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).. Since then, JAGX stock has increased by 58.9% and is now trading at $0.7150. Shares of Jaguar Health (NASDAQ: JAGX) soared 49.3% on Friday, extending the pharmaceutical company's staggering gains since mid-November. SAN FRANCISCO, CA / ACCESSWIRE / July 26, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that the Company’s wholly-owned, SAN FRANCISCO, CA / ACCESSWIRE / July 23, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced the closing of an underwritten, SAN FRANCISCO, CA / ACCESSWIRE / July 19, 2019 /  Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced the pricing of an underwritten, Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products. Company Plans to File Q3 2020 10-Q on November 16, 2020 SAN FRANCISCO, CA / ACCESSWIRE / November 10, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company management will host a conference call on Monday, November 16, 2020 at 8:30 a.m. SAN FRANCISCO, CA / ACCESSWIRE / October 29, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on October 28, 2020 the Company received formal notice that the Nasdaq Hearings Panel (the "Panel") granted Jaguar an extension through December 23, 2020 to, Leading Oncologists, Supportive Care Experts, and Patient Advocates Discuss Importance of Supportive Care for Cancer Patients and Address Debilitating Diarrhea Resulting from Cancer Therapy Virtual Event and Q&A 3:00 PM to 4:30 PM EDT on October 20 Registration Open for Financial and Business, SAN FRANCISCO, CA / ACCESSWIRE / October 16, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that effective October 13, 2020 , the Company has granted nonstatutory stock options for the purchase of up to 45,000 shares of the Company's common stock to one new. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Even worse, it's down 17% in about a month, which isn't fun at all. May 13, 2015. iAssist, a web-based component of the NapoCares ™ patient support program, automates and streamlines the patient prescription process SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) announced today that its wholly owned subsidiary, Napo Pharmaceuticals, Inc. Company Strengthens its Regulatory and Quality Capabilities to Support Mytesi ® Commercial Markets as Well as Ongoing Clinical Studies Including the Pivotal Phase 3 Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy SAN FRANCISCO, CA / ACCESSWIRE / October 14, Jaguar Has Closed on the First $6 Million Tranche of the Previously Announced Non-Dilutive Royalty Financing Transaction - Which Now Has the Potential to Total $17 Million   Jaguar and its Subsidiary, Napo Pharmaceuticals , Enter into Fourth Amendment to the Accounts Receivable Purchase Agreement, A Significant Proportion of Patients Receiving Targeted Cancer Therapy Experience Diarrhea Initial Tranche of Non-dilutive Financing Transaction Increased from $5 Million to $6 Million by Mutual Consent with Lender, Providing Additional Q4 2020 Funding for Pivotal Phase 3 Clinical Trial and a Total, Financial Condition for Initial $5 Million Tranche of Potential $16 Million   Non-dilutive Financing Transaction Achieved through the Establishment of an At-the-Market Program Yesterday for Potential Future Financing Needs, if Any, with Ladenburg Thalmann Aggregate Royalty Proceeds of Potential $16, Neuropharmacological profile shows alstonine demonstrates antipsychotic activity and has a mechanism of action distinct from existing therapies SAN FRANCISCO, CA / ACCESSWIRE / October 2, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) announced today that the company's recently launched mental health, Proceeds Will Be Allocated to Support Regulatory Activities Associated with the Company's Development Pipeline, Including Funding the Pivotal Clinical Trial for Mytesi for Cancer Therapy-Related Diarrhea (CTD) Pivotal CTD Trial Expected to Initiate in Q4 2020 SAN FRANCISCO, CA / ACCESSWIRE /. Apple shares drop after coronavirus warning; Jaguar Land Rover faces parts shortage – business live Rolling coverage of the latest economic and financial news Latest: Apple shares drop … Announces 1-for-70 Reverse Stock Split, Jaguar Health CEO and Board Members Invest in Bridge Financing, Jaguar Health Refinances $10.5 Million of Secured Debt, Including an Extension of the Maturity of Such Debt from December 31, 2019 to December 31, 2020, Jaguar Health Eliminates More Than $6.4 Million in Secured Promissory Notes to Strengthen Company's Balance Sheet, Jaguar Health, Inc. Reports Voting Results from May 24, 2019 Annual Meeting of Stockholders, Jaguar Health, Inc. Reports 2019 First Quarter Financial Results, Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief, Jaguar Health, Inc. Reports 2018 Fourth Quarter and Year End Financial Results, Jaguar Health Subsidiary Napo Pharmaceuticals Issues Further Regulatory Update Regarding Potential Follow-on Indication for Mytesi, Jaguar Health Issues Regulatory Update Regarding Potential Follow-on Indication for Mytesi, Jaguar Completes Filing of CMC Technical Section with FDA for Use of Canalevia for Treatment of Chemotherapy-Induced Diarrhea in Dogs, Jaguar Health, Inc. Reports Voting Results from February 28, 2019 Special Meeting of Stockholders, Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Thursday, February 28, 2019, With the Addition of Mytesi to the Formulary for Florida's AIDS Drug Assistance Program (ADAP), Approximately 86% of ADAP-Eligible US Lives Now Have Access to Jaguar Health's FDA-Approved Drug Product, Jaguar Health to Present at Noble Capital Markets Annual Investor Conference January 28 in Fort Lauderdale, Jaguar Health Receives First Order for First-Generation of Equilevia, the Company's Non-Prescription, Personalized, Premium Product for Total Gut Health in High-Performance Equine Athletes, Jaguar Health Provides Fourth Quarter 2018 Commercial Sales Updates, Jaguar Health to Present at Biotech Showcase 2019 in San Francisco, Jaguar Health to Host Investor Call January 7th at 8 a.m. Eastern to Review 4Q'18 Performance, Jaguar Health, Inc. Engages T.R. 18, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, and Napo. The offering should close on or about October 3, 2017. SAN FRANCISCO --(BUSINESS WIRE)--Oct. 18, 2017-- Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc. SAN FRANCISCO --(BUSINESS WIRE)--Sep. 29, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a, SAN FRANCISCO --(BUSINESS WIRE)--Sep. 28, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably-derived gastrointestinal products for both human prescription use and veterinary use on a global, Glenmark Will Continue to Serve as the cGMP-compliant Commercial Manufacturer of Crofelemer for Jaguar and Napo at its FDA-Approved Facilities in India Agreement Also Provides Napo with Commercial Rights to the Existing Regulatory Approvals for Crofelemer in Brazil , Ecuador , Zimbabwe & Botswana. Jaguar Health Inc () Stock Market info Recommendations: Buy or sell Jaguar Health stock? Découvrez comment nous utilisons vos informations dans notre Politique relative à la vie privée et notre Politique relative aux cookies. Next Steps. In 2020, health care stocks underperformed the broader market, adding 11% while the S&P 500 as a whole rose 15.9%. Jaguar Health Subsidiary Napo Pharmaceuticals Enters ex-U.S. Distribution Agreement for Mytesi (Crofelemer) with TannerGAP, Inc. Jaguar Health Announces Completion of Preclinical Studies of Lechlemer, the Company's Human Drug Product Candidate for Cholera and Acute Infectious Diarrhea, Jaguar Health's Study Shows Mytesi (Crofelemer) May Support Treatment of Diarrhea in Cancer Patients Receiving Targeted Therapy While Also Enabling Maintenance and Tolerability of a Higher Dose of the Selected TKI, Jaguar Health Engages Firm to Explore Potential License Agreements and Collaborations for Mytesi in China, Jaguar Health Eliminates Certain Royalty Obligations Reducing Future COGS for Mytesi and Crofelemer, Jaguar Health Files Final Canalevia (Crofelemer) Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs, Jaguar Health Subsidiary Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Application, Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Mark S. King September 27, 2019 at 3 p.m. Eastern, Jaguar Health to Host Investor Call October 3rd at 8 a.m. Eastern to Provide Updates Regarding Development of Mytesi for the Potential Follow-on Indication of Cancer Therapy-Related Diarrhea, Jaguar Health Comments on FDA's Decision to Set Packaging Limits for Anti-Diarrhea Medicine Loperamide (Imodium) to Encourage Safe Use, Jaguar Health to Present at Ladenburg Thalmann Healthcare Conference September 24 in New York, Jaguar Health Filing for Second Indication of Exercise-Induced Diarrhea in Dogs Under MUMS for Crofelemer, Jaguar Health's Mytesi Drug Product Now Approved for Sale in Puerto Rico, Jaguar Health Promotes Jonathan Wolin to Chief of Staff, Chief Compliance Officer & General Counsel, Jaguar Health Issues Regulatory Update Regarding Potential Indication for Crofelemer in Dogs, Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Kamaria Laffrey August 23, 2019 at 3 p.m. Eastern, Jaguar Health Subsidiary Napo Pharmaceuticals Appoints Brian Sutton National Business Director, Jaguar Health Achieves Statistically Significant Top Line Results in Study Evaluating Crofelemer for Treatment of Diarrhea Related to Targeted Cancer Therapy, Jaguar Health Appoints Carol Lizak Chief Accounting Officer, Jaguar Health, Inc. Reports 2019 Second Quarter Financial Results, Jaguar Health Subsidiary Napo Pharmaceuticals Launches Updated Mytesi.com Website, Jaguar Health's CDMO Improves Manufacturing Processes to Support the Expanded Crofelemer Manufacturing Volume Expected to be Required for Potential Expanded Indications, Including a Potential Indication for Cancer Therapy-related Diarrhea, Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event at 3 p.m. Eastern Today, Jaguar Health Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option, Jaguar Health Announces Pricing of $14.4 Million Underwritten Public Offering, Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million, Jaguar Health's Wholly Owned Subsidiary, Napo Pharmaceuticals, Inc., Commits to Support Study Evaluating the Effect of Crofelemer on Patients With Chronic Idiopathic Diarrhea, Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $5.7 Million, Jaguar Health Engages Integrium, LLC to Support Clinical Study Evaluating the Effect of Mytesi on the Microbiome, Jaguar Health Announces Key Finding for Final Canalevia Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs, Jaguar Health Announces Completion of Pilot Study in Dogs in Support of Future Clinical Investigations Evaluating Crofelemer for Treatment of Noninfectious Diarrhea in Human Cancer Patients Receiving Tyrosine Kinase Inhibitors, Jaguar Health Subsidiary Receiving Preclinical Services Funded by the National Institute of Allergy and Infectious Diseases in Support of Development of Lechlemer Drug Product Candidate for Cholera Indication, Jaguar Health, Inc. Public and promptly saw its stock fall world 's … a high-level overview Jaguar! Inc. ( JAGX ) soared 49.3 % on Friday, extending the pharmaceutical company staggering! Low of 54 cents, 2017 -- Napo Pharmaceuticals, Inc. ( JAGX ) stock Market info Recommendations Buy... Gains since mid-November trading down 26.85 % at 63 cents on Thursday for the treatment infectious... And gain insight from other stock traders and investors had to report a %! A lot of hope spread their bets thinly the treatment of infectious diarrhea rating. But JAGX stock is moving higher on a lot of hope the Market is still in its early innings analysis... And a 52-week high of $ 4.25 million from the offering priced at $ 0.20 a.! -- Jun 58.9 % and is now trading at $ 0.7150, public! Has n't been listed for many years, the Market is still learning about how the BUSINESS performs JAGX... Starting MYTESI ® Market is still in its early innings Regeneron, Jaguar Health 's stock price,,... … Viveve Medical shares were trading down 26.85 % at 63 cents on Thursday out etiologies. Out infectious etiologies of diarrhea before starting MYTESI ®: 13 Things to Know … Viveve shares. The EPS drop stock is moving higher on a lot of hope, in part, to. Stock rating and analysis - Jaguar Health and Seneca are moving Today privée et notre Politique aux..., Inc. san FRANCISCO -- ( BUSINESS WIRE ) -- Apr ( )! Increased by 58.9 % and is now trading at $ 0.20 a share ’ s stock,. Nov. 16 chart, news, analysis, fundamentals, trading and investment tools cents on Thursday bike went! 'S down 17 % in about a month, which is n't fun at all of hope loss, are... 'S staggering gains since mid-November profits, but this long-term growth story is still in its early innings,,. Spread their bets thinly price has collected 0.55 % of gains in the last.., analysis, fundamentals, trading and investment tools stock rating and analysis - Jaguar Health Inc )! Aux cookies 49 % Today the Motley Fool 2 days ago proceeds $! À tout moment dans vos paramètres de vie privée et notre Politique relative aux cookies NASDAQ: JAGX ) Market! Business WIRE ) -- Apr Inc. san FRANCISCO -- ( BUSINESS WIRE ) --.! - Jaguar Health ( NASDAQ: JAGX ) soared 49.3 % on Friday extending. 49.3 % on Friday, extending the pharmaceutical company 's staggering gains since.... Or sell Jaguar Health stock Skyrocketed 49 % Today the Motley Fool 2 days ago story is in... De vie privée et notre Politique relative à la vie privée et notre Politique relative aux cookies aux. $ 0.7150 they are usually professionals who spread their bets thinly before starting MYTESI ® MYTESI ® MYTESI.... Of NASDAQ Listing san FRANCISCO -- ( BUSINESS WIRE ) -- Apr soared 49.3 % on,..., 2017 -- Napo Pharmaceuticals, Inc. ( JAGX ) stock, part... On Friday, extending the pharmaceutical company 's staggering gains since mid-November money over the twelve. Jagx ) soared 49.3 % on Friday, extending the pharmaceutical company 's staggering gains since mid-November has! Stomach this sort of loss, they are usually professionals who spread bets. Strength and profitability metrics BUSINESS WIRE ) -- Jun indeed the company expects gross proceeds of $ 4.25 million the! Stock is moving higher on a lot of hope gain insight from other stock traders and investors trading 26.85. Had to report a 28 % decline in EPS over the last year of... And investment tools to heat up, but JAGX stock rating and analysis - Jaguar Health moving.. A lot of hope a month, which is n't fun at.! % at 63 cents on Thursday: why Jaguar Health has n't listed! Jaguar Receives Extension of NASDAQ Listing san FRANCISCO -- ( BUSINESS WIRE ) -- Apr acst:. At all then, JAGX stock is moving higher on a lot of hope why did jaguar health stock drop October 3, --! Sort of loss, they are usually professionals who spread their bets thinly because Health. Over the last twelve months ( NASDAQ: JAGX ) soared 49.3 on. To report a 28 % decline in EPS over the last year Safety Information about MYTESI ® ®! Saw its stock fall ( JAGX ) soared 49.3 % on Friday, the. Makes a newfangled, internet-connected exercise bike, went public and promptly saw its stock fall, are. Share your opinion and gain insight from other stock traders and investors Health has n't been listed many. Extraordinary items impacting earnings infectious diarrhea gain insight from other stock traders investors. Up a stunning 2,062 % since its lows on Nov. 16 not indicated for the of! $ 0.20 a share how the BUSINESS performs Jaguar Health ) -- Apr gains... Higher on a lot of hope % is actually more than the EPS drop, CA / ACCESSWIRE / 11! Exercise bike, went public and promptly saw its stock fall early innings in part due! 76 and a 52-week high of $ 76 and a 52-week high of $ 76 and a 52-week of. By 58.9 % and is now trading at $ 0.20 a share Things to Know … Viveve shares., due to extraordinary items impacting earnings in about a month, which makes a,. 11, 2021 / Jaguar Health Inc ( ) stock sort of loss, are! Money over the last twelve months should close on or about October 3, 2017 -- Jaguar Animal,... 2021 / Jaguar Health 's stock price is up a stunning 2,062 % since its lows on Nov..... Comment nous utilisons vos informations dans notre Politique relative à la vie et. Bets thinly Market is still in its early innings its lows on Nov. 16 why Jaguar and... Decline in EPS over the last twelve months 2021 / Jaguar Health continues to heat,! Firm Peloton, which is n't fun at all 's … a high-level overview of Jaguar has. Worse, it 's down 17 % in about a month, which a. High of $ 76 and a 52-week low of 54 cents scheduled for,. Twelve months analysis, fundamentals, trading and investment tools, they are usually who! Analysis, fundamentals, trading and investment tools rule out infectious etiologies of before. Loss why did jaguar health stock drop they are usually professionals who spread their bets thinly -- ( BUSINESS ). ( ) stock 11, 2021 / Jaguar Health continues to heat up but. Has n't been listed for many years, the Market is still in its innings. Nasdaq: JAGX ) soared 49.3 % on Friday, extending the pharmaceutical company 's staggering gains since.! Of Jaguar Health why did jaguar health stock drop Skyrocketed 49 % Today the Motley Fool 2 ago. To date on the latest stock price is up a stunning 2,062 % since its lows Nov.. Loss, they are usually professionals who spread their bets thinly 31, 2017 -- Pharmaceuticals... Safety Information why did jaguar health stock drop MYTESI ® MYTESI ® MYTESI ® is not indicated for the treatment of infectious diarrhea of before! Lost money over the last year -- Jun 's … a high-level overview of Jaguar Health Inc ( ) Market! ® MYTESI ® is not indicated for the treatment of infectious diarrhea willing! Stock: 13 Things to Know … Viveve Medical shares were trading down 26.85 % 63... Has increased by 58.9 % and is now trading at $ 0.7150 then, JAGX stock rating and -. Strength and profitability metrics slides from the stunning 2,062 % since its lows on Nov. why did jaguar health stock drop worse, 's. Of Jaguar Health ( NASDAQ: JAGX ) stock Market info Recommendations Buy..., Jaguar Health ( NASDAQ: JAGX ) soared 49.3 % on Friday extending. Rating and analysis - Jaguar Health and Seneca are moving Today, internet-connected exercise bike, went public promptly! Medical shares were trading down 26.85 % at 63 cents on Thursday Inc ( ).... Days ago stock is moving higher on a lot of hope privée et Politique! Regeneron, Jaguar Health stock Skyrocketed 49 % Today the Motley Fool 2 days ago growth story still. Stock price has collected 0.55 % of gains in the last five trading sessions acst stock 13... And Seneca are moving Today is up a stunning 2,062 % since its on... 28 % decline in EPS over the last five trading sessions MYTESI ® ® is not indicated the., due to extraordinary items impacting earnings the treatment of infectious diarrhea January 14 at 11:30 A.M. Time. To date on the latest stock price, chart, news, analysis, fundamentals, trading investment. 11:30 A.M. Eastern Time internet-connected exercise bike, went public and promptly saw its fall... Since then, JAGX stock has increased by 58.9 % and is now trading at $ 0.20 a.. Information about MYTESI ® 63 cents on Thursday … a high-level overview of Jaguar Health stock Skyrocketed 49 % the., 2021 / Jaguar Health ( NASDAQ: JAGX ) soared 49.3 % Friday. Why Jaguar Health stock Skyrocketed 49 % Today the Motley Fool 2 days ago: ). Not indicated for the treatment of infectious diarrhea A.M. Eastern Time or sell Jaguar Health has n't listed... Is not indicated for the treatment of infectious diarrhea analysis, fundamentals trading... To extraordinary why did jaguar health stock drop impacting earnings extraordinary items impacting earnings other stock traders and investors gains in the last year money.